

# Welcome and Updates

Pooja Khatri, MD, MSc

NIH StrokeNET National Coordinating Center
University of Cincinnati







## Agenda—Morning

8:45 am – 9:15 am	Welcome/Updates NDMC NINDS	Pooja Khatri Jordan Elm Scott Janis
9:15 am – 9:30 am	Training Core Update	Randy Marshall Devin Brown
9:30 am – 9:45 am	CRP Core Update	Heena <u>Olalde</u> Kinga Aitken
9:45 am – 10:45 am	ARCADIA-CSI Final Results & ARCADIA Secondary Results Discussion	David Tirschwell Maarten Lansberg Ron Lazar Hooman Kamel
10:45 am – 11:30 am	Themes for priority setting conferences	Pooja Khatri Steve Cramer Karen Johnston Hooman Kamel
11:30 am – 12:00 pm	Break and grab lunch to bring back to the room	



## Agenda—Afternoon

#### \*\*\*Reassemble in Salon at 12:00pm for working lunch\*\*\*

12:00 pm – 12:45 pm Keynote Speaker

"Embedding pragmatic trials within emergency and critical care"

Matthew Semler, MD

Associate Professor of Medicine, Anesthesiology,

and Biomedical Informatics

Associate Director of the Medical Intensive Care Unit

Director, Center for Learning Healthcare

Vanderbilt University

\*\*Please Note: The breakout sessions below will not be livestreamed. Remote attendees rejoin at 2:15pm\*\*

12:45 pm – 2:00 pm Breakout session: Small group discussion on themes for priority setting

conferences. There will be 3 groups:

Recovery Group
 Florida
 Sean Savitz, Maarten Lansberg
 Cheryl Bushnell, Randy Marshall

Acute Group Salon C Enrique Leira, Mark Alberts

2:00 pm – 2:15 pm Break

2:15 pm – 3:15 pm Reassemble in Salon: Moderators to summarize small group discussions

for larger group considerations. Each group will have 10 minutes for

summary and 10 minutes for Q&A.

3:15 pm – 3:30 pm Questions/wrap-up



### Housekeeping

- Wifi Marriott Conference
  - Access code: encore (don't need room #)
- Online link: <a href="https://tinyurl.com/4b3pw3n8">https://tinyurl.com/4b3pw3n8</a>
- Restrooms towards lobby (two rights after exiting room)
- Charging stations are on left and right of room
- Can leave luggage in Salon B (locked during mtg)
- Parking passes see Rose or Kristine if not in your name badge holder
- Airport buses at 4pm
- Please ask your questions and bring your ideas today!





### Trial Portfolio as of Today

#### **9 Studies Completed**

- 6 Definitive (including 2 platform) and 2 Pilot Trials
- 1 Ancillary Study

#### 1 Paused

#### **15 Ongoing Studies**

• 11 Trials, 3 Ancillary Studies, 1 Biomarker Validation Study

#### 1 New Trial Funded



### **Completed Studies**



#### **PREVENTION OF STROKE (2)**

**ARCADIA** No evidence of benefit of apixaban for stroke with evidence of atrial cardiopathy

 ARCADIA-CSI Cognition and silent infarcts – final results pending

# PRIMARY STROKE PREVENTION IN COVID (2)

**ACTIV 4C Platform** Antithrombotic approach for patients discharged from hospital with COVID-19

**ACTIV 4A Platform** Antithrombotic approach for inpatient COVID-19 pts

#### **ACUTE STROKE TREATMENT (4)**

MISTIE 3 No evidence of benefit of minimally invasive surgery for ICH evacuation

**DEFUSE 3** Large treatment benefit of EVT for imaging selected patients at 4.5-16h from onset

**I-DEF** Futility of deferoxamine for three-month outcomes after ICH

**MOST** No evidence of benefit of adjunctive epfibatide or argatroban with intravenous thrombolysis

#### **STROKE RECOVERY & REHABILITATION (1)**

**TELEREHAB** Noninferiority of telehealth to in-person, dose-matched post-stroke rehabilitation





















## **Completed Studies**
























**ARCADIA** No evidence of benefit of apixaban for stroke with evidence of atrial cardiopathy

**ARCADIA-CSI** Cognition and silent infarcts – final results pending



**ACTIV 4C Platform** Antithrombotic approach for patients discharged from hospital with COVID-19

**ACTIV 4A Platform** Antithrombotic approach for inpatient COVID-19 pts



ARCADIA primary paper (JAMA) Secondary analyses today ARCADIA CSI primary results today

Therapeutically anticoagulated noncritically ill pts but not critically ill pts (NEJM X 2)

No benefit of P2Y12 Inhibitors, SGLT2 inhibitors, or P-Selectin-Inhibitor Crizanlizumab (JAMA, Lancet Diabetes Endocrin, Circulation)







## **Completed Studies**



Paved for next ICH evac trials

Global impact on acute stroke care

Raised awareness of 6 month outcomes for ICH

Primary paper in NEJM this month

Precursor to newly funded Telerehab-2



MISTIE 3 No evidence of benefit of minimally invasive surgery for ICH evacuation

**DEFUSE 3** Large treatment benefit of EVT for imaging selected patients at 4.5-16h from onset

**I-DEF** Futility of deferoxamine for threemonth outcomes after ICH

**MOST** No evidence of benefit of adjunctive epfibatide or argatroban with intravenous thrombolysis

#### STROKE RECOVERY & REHABILITATION (1)

**TELEREHAB** Noninferiority of telehealth to in-person, dose-matched post-stroke rehabilitation





















## 15 Ongoing Trials/Studies



#### **PREVENTION OF STROKE (9)**

**CREST-2** Endarterectomy/stenting of asymptomatic carotid stenosis (N=2486/2480)

 CREST-H Cognitive outcomes in hemodynamically impaired subset (N=392/385)

**Sleep-SMART** Treatment of obstructive sleep apnea (Ph 3, N=1601/3062)

**SATURN** Statin continuation in ICH survivors (N=600/1426)

SATURN-MRI Silent stroke (N=229/894)

**ASPIRE** Apixiban for afib after ICH (N=340/700)

**CAPTIVA** Anticoagulation vs antiplatelets for intracranial stenosis (N=514/1683)

 CAPTIVA MRI Biomarkers of recurrent stroke in intracranial atherosclerotic stenosis (N=3/300)

**FOCAS** Corticosteroids for pediatric stroke due to focal cerebral arteriopathy (N=8/80)

#### **ACUTE STROKE TREATMENT (3)**

**FASTEST** FVIIa for acute ICH (N=543/860)

**SISTER** Novel clot-dissolving Ab, TS23, for ischemic stroke (N=9/300)

**STEP Platform** Registry-supported trial platform to optimize outcomes after LVO and MVO

#### **STROKE RECOVERY & REHABILITATION (3)**

**TRANSPORT-2** Transcranial direct stimulation for UE recovery (N=129/129)

**I-ACQUIRE** Intensive infant rehabilitation for ischemic stroke (N=215/216)

**VERIFY** Acute prediction of UE motor recovery and function (N=252/657)

**Telerehab-2** Telehealth in home vs usual care for UE motor function (N=0/202)





























### **Prevention Updates**



#### **PREVENTION OF STROKE (9)**

**CREST-2** Endarterectomy/stenting of asymptomatic carotid stenosis (N=2486/2480)

 CREST-H Cognitive outcomes in hemodynamically impaired subset (N=392/385)

**Sleep-SMART** Treatment of obstructive sleep apnea (Ph 3, N=1601/3062)

**SATURN** Statin continuation in ICH survivors (N=600/1426)


• SATURN-MRI Silent stroke (N=229/894)

**ASPIRE** Apixiban for afib after ICH (N=340/700)

**CAPTIVA** Anticoagulation vs antiplatelets for intracranial stenosis (N=514/1683)

 CAPTIVA MRI Biomarkers of recurrent stroke in intracranial atherosclerotic stenosis (N=3/300)

**FOCAS** Corticosteroids for pediatric stroke due to focal cerebral arteriopathy (N=8/80)



CREST-H in follow up as well!

Prevention aim on hold as of 28/JUN/2024

Recovery aim ongoing (sample size reduction)































### Acute and Recovery Updates





**FASTEST** FVIIa for acute ICH (N=543/860)

**SISTER** Novel clot-dissolving Ab, TS23, for ischemic stroke (N=9/300)

**STEP Platform** Registry-supported trial platform to optimize outcomes after LVO and MVO




**TRANSPORT-2** Transcranial direct stimulation for UE recovery (N=129/129)

**I-ACQUIRE** Intensive infant rehabilitation for ischemic stroke (N=215/216)

**VERIFY** Acute prediction of UE motor recovery and function (N=252/657)

**Telerehab-2** Telehealth in home vs usual care for UE motor function (startup, N=202)




Key interim analysis in December


FDA approved amendment to incorporate an enrichment and promising zone design



New assets under active development



Anticipate results at ISC 2025




































## >13,000 Enrolled and >7000 Randomized



#### >13,000 Enrolled and >7000 Randomized



#### **Examples of Innovative Design Features**

- Adaptive enrichment DEFUSE-3
- Multi-arm, multistage MOST, CAPTIVA
- Patient-Reported Outcome -- Utility-weighted modified Rankin MOST, FASTEST, STEP
- Covariate adjusted randomization Telerehab, iACQUIRE, MOST, SATURN, TRANSPORT2
- Response adaptive randomization Sleep SMART, MOST, SISTER, STEP
- Sample size re-estimation ARCADIA, Sleep SMART, ASPIRE, SATURN
- Step forward randomization FASTEST
- Emergency consent FASTEST
- Infant population iACQUIRE
- Utility function SISTER
- Randomized, embedded, multifactorial, adaptive platform (REMAP) STEP
- Registry-supported STEP



#### **International Trials**

## NIH StrokeNet Network Standard Operating Procedure

SOP Number: ADM 27

SOP Name: Management of StrokeNet Trials with International Sites

Effective Date: 09/24/2024







### StrokeNet Trials Publications (Last One Year)

JAMA | Original Investigation

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy

The ARCADIA Randomized Clinical Trial

JAMA Neurology | Original Investigation

Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial



Stroke: Vascular and Interventional Neurology

#### ORIGINAL RESEARCH

CREST-2 Commitment to Rigorous Assessment of Carotid Stenting for Primary Prevention of Stroke

Circulation

Volume 148, Issue 5, 1 August 2023; Pages 381-390 https://doi.org/10.1161/CIRCULATIONAHA.123.065190



ORIGINAL RESEARCH ARTICLE

Effect of the P-Selectin Inhibitor Crizanlizumab on

Survival F

for COVID

Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke



## **Committee Updates**

		CHAIRS
Working	Acute	Karen Johnston, MD & Jeff Saver, MD
Groups Prevention		Hooman Kamel, MD & Scott Kasner MD
	Recovery	Steve Cramer, MD & Steven Wolf, PT PhD
Cores	Fellow Education/Training	Randy Marshall, MD & Devin Brown, MD
	CRP Education/Training (new)	Heena Olalde, RN, MSN & Kinga Aitken, MPH, CCRP
	Diversity/Equity/Inclusion (new)	B. Boden-Albala, MPH, DrPH & L. Skolarus, MD
Advisory	Patient Rep/Advocacy (new)	Flannery O'Neil, MPH & Aqualyn Kennedy, MBA
	Pediatrics	Heather Fullerton, MD
	Preclinical (new)	Lauren Sansing, MD
	Telestroke	Chris Streib, MD & Abbey Staugaitis, RN, MSN, CCRC



## **Committee Updates**

Working	Acute	Membership rotated;
Groups	Prevention	Trial development;
H	Recovery	Scientific themes for priority setting conferences
Cores	Fellow Education/Training CRP Education/Training (new)	Stay tuned today
	Diversity/Equity/Inclusion (new)	Formed group—attending WGs—how to collect baseline demographics and analysing demographics of ongoing trials
Advisory	Patient Rep/Advocacy (new)	Expanded involvement, STEP ICF
	Pediatrics	Formed group –attdg WGs – STEP protocol
	Preclinical (new)	Formed group – attdg WGs
	Telestroke	Remote Consent Practices Survey, MOST eCONSENT pub (higher enrollment, fewer ICF PVs)

